Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.

You may also be interested in...

Estimated FDA User Fee Review Goals For Pending NDAs/BLAs


Watchdog Group Revives Concerns Over Symlin Dosing Instructions

FDA's internal review of the dosing instructions for Amylin's antidiabetic Symlin likely will revisit dosing-related concerns first identified during its NDA review

Symlin Complete Response Follows "Emerging Consensus" On Hypoglycemia

Amylin expects its hypoglycemia re-analysis to mitigate FDA’s concerns about its pending antidiabetic Symlin, the company says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts